Andrx abandons brand-name drug business

Share this article:
Andrx is selling off its brand-name pharmaceutical business and ending its supply and distribution contract with Pfizer for its hypertension drug Cardura XL.
Andrx decided to shed its brand-name division to focus on development and distribution. The company will end its contract with Pfizer for Cardura XL because the drug failed to win FDA approval by Dec. 31. Andrx is seeking a refund of the $10 million it paid Pfizer in connection with the agreement for Cardura XL, exercising its right to end the November 2003 deal.
Andrx retained Banc of America Securities to seek offers for its brand-name business, which sustained operating losses of about $31 million for the first nine months of 2004.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.